Emcure Pharmaceuticals Limited — Updates, 04-04-2025: Press Release

Tillomed Laboratories Limited, a subsidiary of Emcure Pharmaceuticals Ltd., has acquired a strategic pharmaceutical portfolio from Manx Healthcare Limited for approximately £19.7 million. This includes £4.7 million allocated for inventory, with £6.2 million to be paid upfront and the remaining amount contingent on milestone payments over the next 18 months. This acquisition is a significant step for Tillomed, enhancing its product offerings and expanding its market reach, ultimately aiming to meet the evolving healthcare needs of patients. The CEO of Tillomed highlighted the importance of this portfolio in diversifying their range and strengthening market presence. With this move, Tillomed aims to provide more accessible healthcare solutions across Europe.